Impact of radiation dose to immune cells on survival in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a retrospective analysis

被引：0

作者：

Zhao, Junfeng ^{[1
]}

Wang, Kang ^{[1
]}

Li, Ying ^{[2
]}

Hu, Xinying ^{[1
]}

Liu, Haoyu ^{[1
]}

Zhao, Jingjing ^{[1
]}

Li, Li ^{[1
,3
]}

Yuan, Shuanghu ^{[1
,3
]}

机构：

[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China

[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan, Shandong, Peoples R China

[3] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Radiat Oncol, Div Life Sci & Med, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China

来源：

BMC CANCER | 2025年 / 25卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Esophageal squamous cell carcinoma; Neoadjuvant chemoradiotherapy; Estimated dose of radiation to immune cells; Lymphocyte nadir; Immune system; LUNG-CANCER; LYMPHOCYTE NADIR; RADIOTHERAPY; THERAPY; LYMPHOPENIA; DURVALUMAB;

D O I：

10.1186/s12885-025-13602-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Neoadjuvant chemoradiotherapy (NCRT) is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). This study aims to explore the effect of the estimated dose of radiation to immune cells (EDRIC) on lymphocytes in patients with locally advanced ESCC undergoing NCRT and evaluate the impact of EDRIC on patient prognosis. Methods This retrospective study included patients with locally advanced ESCC who received NCRT followed by radical esophagectomy at our institution between March 2016 and December 2022. EDRIC was calculated as a function of the number of fractions and the average doses to the lungs, heart, and remaining body. The optimal cut-off value of EDRIC was determined based on disease-free survival (DFS), and patients were divided into two groups according to this cut-off value. Kaplan-Meier and Cox proportional hazards regression analyses were used to estimate overall survival (OS) and DFS. Results The 182 patients included in the study had a mean EDRIC of 5.41 +/- 1.70 Gy and an EDRIC cut-off value of 6.86 Gy. Patients with an EDRIC <= 6.86 Gy had a significant advantage in DFS (hazard ratio [HR]: 0.37, 95% confidence interval [CI]: 0.20-0.68, P = 0.001) and OS (HR: 0.22, 95% CI: 0.10-0.48, P = 0.001). EDRIC was closely associated with the lymphocyte nadir (P < 0.001) and lymphocytopenia values (P < 0.001). Patients with a lymphocyte nadir <= 0.16 x 109/L had poorer DFS (HR: 2.04, 95% CI: 1.07-3.88, P = 0.025) and OS (HR: 2.52, 95% CI: 1.14-5.56, P = 0.018). Conclusion EDRIC is an independent prognostic factor for patients with locally advanced ESCC undergoing NCRT. A higher EDRIC is associated with poorer DFS and OS and is closely related to reduced lymphocyte counts. As a quantifiable parameter, future research should explore methods of lowering EDRIC during NCRT while ensuring adequate tumor coverage and sufficient dosage.

引用

页数：11

共 41 条

[1] Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer [J].

Abravan, Azadeh ;

Faivre-Finn, Corinne ;

Kennedy, Jason ;

McWilliam, Alan ;

van Herk, Marcel .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) :1624-1635

[2] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].

Altorki, Nasser K. ;

McGraw, Timothy E. ;

Borczuk, Alain C. ;

Saxena, Ashish ;

Port, Jeffrey L. ;

Stiles, Brendon M. ;

Lee, Benjamin E. ;

Sanfilippo, Nicholas J. ;

Scheff, Ronald J. ;

Pua, Bradley B. ;

Gruden, James F. ;

Christos, Paul J. ;

Spinelli, Cathy ;

Gakuria, Joyce ;

Uppal, Manik ;

Binder, Bhavneet ;

Elemento, Olivier ;

Ballman, Karla, V ;

Formenti, Silvia C. .

LANCET ONCOLOGY, 2021, 22 (06) :824-835

[3] Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer [J].

Bradley, Jeffrey D. ;

Hu, Chen ;

Komaki, Ritsuko R. ;

Masters, Gregory A. ;

Blumenschein, George R. ;

Schild, Steven E. ;

Bogart, Jeffrey A. ;

Forster, Kenneth M. ;

Magliocco, Anthony M. ;

Kavadi, Vivek S. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Clifford G. ;

Wynn, Raymond B. ;

Koprowski, Christopher D. ;

Olson, Michael R. ;

Meng, Joanne ;

Paulus, Rebecca ;

Curran, Walter J., Jr. ;

Choy, Hak .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) :706-+

[4] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].

Bradley, Jeffrey D. ;

Paulus, Rebecca ;

Komaki, Ritsuko ;

Masters, Gregory ;

Blumenschein, George ;

Schild, Steven ;

Bogart, Jeffrey ;

Hu, Chen ;

Forster, Kenneth ;

Magliocco, Anthony ;

Kavadi, Vivek ;

Garces, Yolanda I. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Cliff ;

Wynn, Raymond B. ;

Koprowski, Christopher ;

Meng, Joanne ;

Beitler, Jonathan ;

Gaur, Rakesh ;

Curran, Walter, Jr. ;

Choy, Hak .

LANCET ONCOLOGY, 2015, 16 (02) :187-199

[5] Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial (vol 402, pg 871, 2023) [J].

Khabir, Yumna .

LANCET, 2023, 402 (10405) :850-850

[6] The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study [J].

Chen, Meng ;

Chen, Kuifei ;

Li, Shuling ;

Meng, Yinnan ;

Shi, Yangyang ;

Chen, Xiaofeng ;

Yang, Haihua .

JOURNAL OF THORACIC DISEASE, 2022, 14 (02) :494-506

[7] Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer [J].

Contreras, Jessika A. ;

Lin, Alexander J. ;

Weiner, Ashley ;

Speirs, Christina ;

Samson, Pamela ;

Mullen, Daniel ;

Campian, Jian ;

Bradley, Jeffrey ;

Roach, Michael ;

Robinson, Clifford .

RADIOTHERAPY AND ONCOLOGY, 2018, 128 (03) :498-504

[8] Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy [J].

Davuluri, Rajayogesh ;

Jiang, Wen ;

Fang, Penny ;

Xu, Cai ;

Komaki, Ritsuko ;

Gomez, Daniel R. ;

Welsh, James ;

Cox, James D. ;

Crane, Christopher H. ;

Hsu, Charles C. ;

Lin, Steven H. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (01) :128-135

[9] Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer [J].

Deek, Matthew P. ;

Benenati, Brian ;

Kim, Sinae ;

Chen, Ting ;

Ahmed, Inaya ;

Zou, Wei ;

Aisner, Joseph ;

Jabbour, Salma K. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (01) :147-154

[10] Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer [J].

Dess, Robert T. ;

Sun, Yilun ;

Matuszak, Martha M. ;

Sun, Grace ;

Soni, Payal D. ;

Bazzi, Latifa ;

Murthy, Venkatesh L. ;

Hearn, Jason W. D. ;

Kong, Feng-Ming ;

Kalemkerian, Gregory P. ;

Hayman, James A. ;

Ten Haken, Randall K. ;

Lawrence, Theodore S. ;

Schipper, Matthew J. ;

Jolly, Shruti .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) :1395-+

← 1 2 3 4 5 →